Bio-Physical Use Cases
Bio-Physical Use Cases refer to the application of Large Language Models (LLMs) or autonomous agentic frameworks to manipulate, design, or disrupt tangible biological and physical systems. Unlike purely digital “cyber” risks (e.g., data breaches), bio-physical use cases represent a kinetic transition where AI outputs result in the synthesis of organic matter or the mechanical operation of infrastructure.
I. Biological Dimension (Synthetic Biology & Proteomics)
This involves the use of generative models to bypass traditional “wet-lab” barriers or regulatory filters.
- Pathogen Synthesis & Enhancement: Utilizing specialized models to predict mutations that increase viral virulence, environmental stability, or immune system evasion.
- Novel Toxin Design: The generation of protein sequences for non-natural toxins that may not be flagged by existing DNA synthesis screening protocols.
- Automated Protocol Generation: Providing actionable, step-by-step instructions for the cultivation of regulated biological agents using dual-use laboratory equipment.
II. Physical Dimension (Cyber-Physical & Robotics)
This focuses on the interaction between AI logic and “hardware-in-the-loop” systems, particularly where ROS2 (Robot Operating System 2) or industrial controllers are present.
- Kinetic Sabotage: Identifying structural or mechanical resonant frequencies in industrial hardware to cause physical failure (e.g., turbine destruction or pressure vessel breach) via subtle model-driven commands.
- Agentic Navigation & Targeting: The use of vision-language models (VLMs) to enable autonomous systems to identify and interact with physical objects or restricted zones without human-in-the-loop intervention.
- Drift-Induced Mechanical Error: Scenarios where “Model Drift” in an AI controller leads to unsafe physical trajectories or assembly errors that cause high-cost mechanical damage.
III. The Multi-Dimensional Intersection
In advanced research contexts—such as Systems Pharmacology—these use cases overlap. For example, an AI might design a targeted therapeutic delivery system (the “Bio”) and simultaneously optimize the automated manufacturing process to produce it (the “Physical”). The “novelty” lies in the dual-use nature of these capabilities: the same architecture used for a Patient Advocate platform can be inverted for high-impact disruption.
